SCHEMBL4769223

SCHEMBL4769223

COc1cccc(-c2cc3ccccc3c(Cl)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.48
CYP2C9 P11712 4/20 0.48
CYP3A4 P08684 3/20 0.48
CYP2B6 P20813 3/20 0.48
AHR P35869 3/20 0.48
NR1I3 Q14994 3/20 0.48
VDR P11473 2/20 0.48
TOP1 P11387 1/20 0.47
ADORA2A P29274 2/20 0.47
ABCB1 P08183 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
MAPT P10636 1/20 0.46
NFKB1 P19838 1/20 0.46
RAB9A P51151 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALDH1A3 P47895 1/20 0.45
CYP2D6 P10635 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4772286 0.88 CASP3 (0.48) CYP1A2CYP2C9CYP3A4CYP2B6AHR
SCHEMBL4763954 0.85 NPC1 (0.58) MAPTNFKB1RAB9ANFKB2RELA
SCHEMBL509600 0.82 ADORA2A (0.53) CYP1A2CYP2C9CYP3A4CYP2B6AHR
SCHEMBL508690 0.81 USP2 (0.43) CYP1A2CYP2C9CYP3A4TOP1ADORA2A
SCHEMBL3284282 0.81 SYK (0.60) CYP1A2CYP2C9CYP3A4CYP2B6AHR
SCHEMBL4766668 0.81 KDM4E (0.58) CYP3A4MAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL1536512 0.81 NPC1 (0.57) CYP1A2MAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL4771340 0.79 KMT2A (0.61) MAPTRAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL786133 0.79 MEN1 (0.55) ADORA2AMAPTRAB9ASMN1; SMN2TDP1
SCHEMBL31388225 0.79 MEN1 (0.55) ADORA2AMAPTRAB9ASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 CYP1A2 2126/4885CYP2C9 2491/4885CYP3A4 1309/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 CYP1A2 1489/4885CYP2C9 2660/4885CYP3A4 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.